Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: A preliminary report

Journal of the American Academy of Dermatology

Volumn 38, Issue 4, 1998, Pages 564-568

  Hodak, E ^a   Yosipovitch, G ^a   David, M ^a   Ingber, A ^a   Chorev, L ^a   Lider, O ^a   Cahalon, L ^a   Cohen, I R ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; LICHEN PLANUS; MALE; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031897574     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(98)70118-5     Document Type: Article

References (17)

1. R Akasu L From HJ. Kahn Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus Am J Dermatopathol 15 1993 217 223
2. AS Boyd KH. Neldner Lichen planus J Am Acad Dermatol 81 1991 294 319
3. ER Farmer AF. Hood Graft-versus-host disease. 4th ed TB Fitzpatrick AZ Eisen K Wolff Dermatology in general medicine. 1993 McGraw-Hill New York 1510 1519
4. PD Pigatto G Chiappino A Bigardi N Mozzanica AF. Finzi Cyclosporin A for treatment of severe lichen planus Br J Dermatol 122 1990 121 123
5. NJ Levell CS Munro JM. Marks Severe lichen planus clears with very low-dose cyclosporin Br J Dermatol 127 1992 66 67
6. O Lider E Baharoav YA Mekori I Miller Y Naparstek I Vlodavsky Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of low molecular weight heparin J Clin Invest 83 1989 752 756
7. A Ingber A Trattner IR Cohen YA. Mekori Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity Acta Derm Venereol (Stockh) 74 1994 454 456
8. PDR (Physician Desk Reference) 51st ed 1997 2187 2189
9. O Lider L Cahalon D Gilat R Hershkoviz D Siegel R Margalit A disaccharide that inhibits tumor necrosis factor–α is formed from the extracellular matrix by the enzyme heparanase Proc Natl Acad Sci U S A 11 1995 5037 5041
10. Y Naparstek IR Cohen Z Fuks I. Vlodavsky Activated T lymphocytes produce a matrix degrading heparin sulfate endoglycosidase Nature 310 1984 241 243
11. N Savion Z Fuks I. Voldavsky T lymphocytes and macrophage interaction with cultured vascular endothelial cells: attachment, invasion and subsequent degradation of the subendothelial extracellular matrix J Cell Physiol 118 1984 169 176
12. R Fridman O Lider Y Naparstek Z Fux I Vlodavsky IR. Cohen Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparin sulfate moiety of subendothelial extracellular matrix J Cell Physiol 130 1987 85 92
13. O Lider YA Mekori T Miller R Bar-Tana I Vlodavsky E Baharav Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell mediated immunity Eur J Immunol 20 1990 493 495
14. L Cahalon O Lider H Schor A Avron D Gilat R Hershkovis Heparin disaccharides inhibit tumor necrosis factor–α production by macrophages and arrest immune inflammation in rodents Intern Immunol 9 1997 1517 1522
15. J Hirsh M. Levine Low molecular weight heparin Blood 19 1992 1 17
16. JO. Andreasen Oral lichen planus. 1. A clinical evaluation of 115 cases Oral Surg Oral Med Oral Pathol 25 1968 31 42
17. RA Strauss L Fattore K. Soltani The association of mucocutaneous lichen planus and chronic liver disease Oral Surg Oral Med Oral Pathol 68 1989 406 410